Compare BridgeBio Pharma Inc (BBIO) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Devon Energy Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Devon Energy Corp trades at $45.35 (market cap $49.90B). The key difference: Devon Energy Corp is far larger — about 3× BridgeBio Pharma Inc's market cap, and Devon Energy Corp pays a 2.82% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DVN | |
|---|---|---|
Market Cap | $16.61B | $49.90B |
Sector | Health | Energy |
52-Week High | $90.17 | $52.07 |
52-Week Low | $47.29 | $31.74 |
Enterprise Value | $18.16B | $60.63B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Devon Energy (DVN) trades at $42.98, down 0.3% with a bearish technical signal. The company reported strong Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising its dividend 33% and accelerating debt reduction. Valuation metrics appear attractive with P/E of 9.34 and EV/EBITDA of 6.59, though net income margins have declined from 31.4% in 2022 to 15.4% in 2025.
The outlook remains positive with 71% analyst buy ratings and a $61.91 consensus price target representing 44% upside. Key catalysts include merger synergies from Coterra integration and strong free cash flow generation supporting shareholder returns. Risks include oil price volatility and execution of the $1B+ synergy target by 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
